Symbols

ZBH

Zimmer Biomet·NYSE

--(--)

ZBH fundamentals

ZBH Q4 2025 Earnings

Zimmer Biomet (ZBH) released its earnings on Feb 10, 2026: revenue was 2.24B (YoY +10.90%), beat estimates; EPS was 2.42 (YoY +4.76%), beat estimates.

Revenue / YoY

2.24B

+10.90%

EPS / YoY

2.42

+4.76%

Report date

Feb 10, 2026

ZBH Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 organic growth 5.4%, U.S. 5.7%, driven by new products and ASC expansion. 2026 guidance: 1-3% growth amid sales force transition.
Sales Force Transformation: Shifting to dedicated reps by 2027, with 200+ new hires in high-growth areas. 2026 disruption expected, but 2027+ productivity gains anticipated.
Financial Highlights: 2025 free cash flow $1.172B (11% YoY). 2026 EPS $8.30-$8.45, with 8-10% free cash flow growth.
Strategic Initiatives: ASC penetration ~20%, mBos robot launch, and iodine-coated implants for Japan. Focus on operational efficiency and shareholder returns.

Earnings

EPS

Revenue

Revenue & Expenses

ZBH has released its 2025 Q4 earnings report, with revenue of 2.24B, reflecting a YoY change of 10.90%, and net profit of 137.90M, showing a YoY change of -42.54%. The Sankey diagram below clearly presents ZBH's revenue sources and cost distribution.

Key Indicators

Zimmer Biomet (ZBH) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Zimmer Biomet (ZBH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Zimmer Biomet (ZBH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Zimmer Biomet (ZBH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown